Certificate of Analysis and Data Sheet

Catalog No.
HIV-104

Source
E.coli

Description :

The protein contains the full-length sequence of HIV-I protein p24 .

Purification method:

Purified by proprietary chromatographic technique.

Purity:

Protein is >95% pure as determined by 10% PAGE (coomassie staining) and RP-HPLC.

Protein conc:

1mg/ml, 50 mM Tris pH 7.2 and 8 M urea.

Storage:

Protein is shipped at ambient temperature. Upon arrival, Store at -20⁰C.

Stability:

ReFive years frozen. One month in solution at room temperature.

Specificity:

Immunoreactive with all sera of HIV-I infected individuals.

Application:

Antigen in ELISA and Western blots, excellent antigen for early detection of HIV seroconvertors with minimal specificity problems.

Label:

Also available:

* Recombinant HIV-Ip24, biotin conjugate.
-Price: $125/100ug, $475/500ug, $900/1000ug.

* Recombinant HIV-Ip24, Horseradish peroxidase labled.
-Price: $125/100ug, $475/500ug, $900/1000ug.

Usage:

This material is offered by ProSpec-TechnoGene for research, laboratory or further evaluation purposes.

Gene:

Name:GAG

Protein synonyms/aliases:

Gag polyprotein (Pr55Gag)

Precursor's functional components:

Matrix protein p17 (MA)
Capsidprotein p24 (CA)
Spacer peptide p2
Nucleocapsid protein p7 (NC);Spacer peptide p1
Protein p6 .

Protein Family:

Protein Domains:

Domains:
•IPR000071   Immunodeficiency lentiviral matrix
•IPR000721   Retroviral nucleocapsid protein Gag
•IPR001878   Zinc finger, CCHC-type

Protein links:

Precursor- Protein structure and amino acid sequence:

Latest Publications:

1. HIV-1 p24 may persist during long-term highly active antiretroviral therapy, increases little during short treatment breaks, and its rebound after treatment stop correlates with CD4(+) T cell loss.
J Acquir Immune Defic Syndr 2005 Nov 1;40(3):250-6
2. Signal-boosted qualitative ultrasensitive p24 antigen assay for diagnosis of subtype C HIV-1 infection in infants under the age of 2 years.
J Acquir Immune Defic Syndr 2005 Aug 1;39(4):391-4
3. Reduced viral burden amongst high responder patients following HIV-1 p24 peptide-based therapeutic immunization.
Vaccine 2005 Jul 1;23(31):4011-5
4. Antibody recognition of synthetic peptides mimicking immunodominant regions of HIV-1 p24 and p17 proteins.
Rev Argent Microbiol 2004 Oct-Dec;36(4):151-7
5. Preserved antigenicity of HIV-1 p24 produced and purified in high yields from plants inoculated with a tobacco mosaic virus (TMV)-derived vector.
J Virol Methods 2004 Nov;121(2):201-8
6. Lowering the detection limits of HIV-1 viral load using real-time immuno-PCR for HIV-1 p24 antigen.
Am J Clin Pathol 2004 Jul;122(1):20-7

採購找生工，預算最輕鬆。

回頁首↑ | 回首頁←

---

中華民國95年06月06日更新